Muhammad Nazar, Brooks Iii Nathaniel, Chatham Lauren, Chatham Anthony, Muthukanagaraj Purushothaman
Psychiatry, Cornerstone Family Healthcare, New York, USA.
Private Privatice Psychiatry, Out Patient Psychiatrist, Phoenix, USA.
Cureus. 2023 Mar 24;15(3):e36634. doi: 10.7759/cureus.36634. eCollection 2023 Mar.
Electroconvulsive therapy (ECT) is a safe and effective treatment modality for various psychiatric disorders. However, evidence suggests a putative role of ECT in treating movement disorders that are refractory to less invasive modalities. ECT is primarily used in treatment-resistant psychiatric disorders. However, growing evidence exists for its use in movement disorders with and without psychiatric comorbidity. The primary objective of this systematic review was to examine the efficacy of ECT as a primary treatment modality for movement disorders. Relevant, peer-reviewed publications were retrieved from PubMed, SCOPUS, CINAHL, and PsycINFO. Keywords related to ECT and movement disorders were used as search phrases to identify relevant articles. A total of 90 articles that met the inclusion criteria were included in this review. Core findings were subsequently appraised on the role of ECT in treating movement disorders. Inclusion and exclusion criteria were developed to guide the search and selection process. Sources that met the inclusion criteria were those published between 2001 and January 2023. Additionally, peer-reviewed journals published in the English language covering the role of ECT in movement disorders were deemed appropriate for inclusion. Sources published before 2001, written in a non-English language, and not from peer-reviewed journals were excluded from this systematic review. The exclusion criteria also entailed eliminating duplicates from the review list. Most reviewed sources revealed that ECT improved outcomes in symptoms associated with various movement symptoms. However, ECT does not have a long-lasting impact on neuroacanthocytosis symptoms. Additionally, ECT is negatively associated with aggression and agitation, two of the most critical movement symptoms of Alzheimer's disease. Evidence affirms the efficacy of ECT in providing symptomatic relief for movement disorders aside from psychiatric comorbidities. This positive association highlights the need for randomized controlled studies to identify movement disorder sub-populations that may respond to ECT.
电休克治疗(ECT)是治疗各种精神障碍的一种安全有效的治疗方式。然而,有证据表明ECT在治疗对侵入性较小的治疗方式无效的运动障碍方面可能发挥作用。ECT主要用于治疗难治性精神障碍。然而,越来越多的证据表明其可用于伴有或不伴有精神共病的运动障碍。本系统评价的主要目的是研究ECT作为运动障碍主要治疗方式的疗效。从PubMed、SCOPUS、CINAHL和PsycINFO中检索了相关的同行评审出版物。使用与ECT和运动障碍相关的关键词作为搜索短语来识别相关文章。本评价共纳入90篇符合纳入标准的文章。随后对ECT在治疗运动障碍中的作用的核心研究结果进行了评估。制定了纳入和排除标准以指导搜索和选择过程。符合纳入标准的来源是2001年至2023年1月期间发表的。此外,以英文发表的涵盖ECT在运动障碍中作用的同行评审期刊被认为适合纳入。2001年以前发表的、非英文撰写的以及非来自同行评审期刊的来源被排除在本系统评价之外。排除标准还包括从评审列表中消除重复项。大多数被评审的来源表明ECT改善了与各种运动症状相关的症状。然而,ECT对神经棘红细胞增多症症状没有持久影响。此外,ECT与攻击行为和激越呈负相关,这是阿尔茨海默病最关键的两种运动症状。有证据证实ECT除了对精神共病外,在缓解运动障碍症状方面是有效的。这种正相关突出了需要进行随机对照研究以确定可能对ECT有反应的运动障碍亚组人群。